hydroxycobalamin
Orphan DrugFDA Approved, EMA Approved
Description
Hydroxycobalamin is a precursor of vitamin B12 with higher tissue retention than cyanocobalamin. It is used in the treatment of methylmalonic acidemia and combined malonic and methylmalonic acidemia by serving as a cofactor for methylmalonyl-CoA mutase. The drug helps convert methylmalonyl-CoA to succinyl-CoA, reducing toxic metabolite accumulation.
Indications & Therapeutic Use
methylmalonic acidemia, combined malonic and methylmalonic acidemia, cyanide poisoning, vitamin B12 deficiency
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
hydroxycobalamin
| Generic Name | hydroxycobalamin |
| Brands | 1 brand available |
| Active Ingredient | hydroxocobalamin |
| Drug Class | methylmalonic acidemia |
| Manufacturer | Recordati Rare Diseases |
| Dosage Forms | intramuscular injection 1000 mcg/mL, intravenous infusion 2.5 g/vial |
| Medical Code | V03AB33 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved, EMA Approved |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes